PMID- 11890992
OWN - NLM
STAT- MEDLINE
DCOM- 20020327
LR  - 20190816
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 133
IP  - 1
DP  - 2002 Feb
TI  - Contribution of fluorescence in situ hybridization to immunohistochemistry for 
      the evaluation of HER-2 in breast cancer.
PG  - 66-71
AB  - The main focus of the present study was to assess the efficacy of interphase 
      cytogenetics using fluorescence in situ hybridization (FISH) as a valid 
      alternative to immunohistochemistry (IHC) in paraffin-embedded tissue sections 
      and/or the efficacy of the combination of the two methods, while, at the same 
      time, aiming to provide additional information on the use of the two methods. For 
      this study, selected breast cancer patients (n=66) were tested for HER-2 gene 
      amplification by FISH. The probe contains DNA sequences specific for the HER-2 
      human gene locus and hybridizes to the 17q11.2 through q12 region of human 
      chromosome 17. The same samples were tested previously for HER-2 overexpression 
      by two monoclonal antibodies (300G9 and CB11), recognizing an extracellular and 
      an internal domain of gp185(Her-2), respectively. HER-2 overexpression also was 
      evaluated using the HerceptTest Kit (Dako, Milan, Italy). The HerceptTest was 
      performed according to the manufacturer's standard procedures, and results were 
      scored on a 0 to 3+ scale. A total of 34 (51%) of 66 breast tumors enrolled in 
      this study were positive by FISH. Of the 34 cases amplified by FISH, 9 were 
      negative by IHC using both monoclonal antibody (MoAb) 300G9 and MoAb CB11, with a 
      concordance rate from 80.3% to 83.3%. A higher concordance was verified (92.4%) 
      when we used the HerceptTest Kit. Of the 32 cases found negative with the 
      HerceptTest, FISH analysis identified HER-2 gene amplification in more than 10%. 
      Our results indicate that with the combined use of both methods, several 
      amplified samples classified negative by IHC can be used thus improving 
      therapeutic planning for specific therapy with the monoclonal antibody 
      trastuzumab.
FAU - Cianciulli, Anna M
AU  - Cianciulli AM
AD  - Department of Clinical Pathology, Regina Elena Cancer Institute, Via Elio 
      Chianesi 53, 00144, Rome, Italy. cianciulli@ifo.it
FAU - Botti, Claudio
AU  - Botti C
FAU - Coletta, Angela M
AU  - Coletta AM
FAU - Buglioni, Simonetta
AU  - Buglioni S
FAU - Marzano, Raffaella
AU  - Marzano R
FAU - Benevolo, Maria
AU  - Benevolo M
FAU - Cione, Antonio
AU  - Cione A
FAU - Mottolese, Marcella
AU  - Mottolese M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*analysis/*genetics
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
EDAT- 2002/03/14 10:00
MHDA- 2002/03/28 10:01
CRDT- 2002/03/14 10:00
PHST- 2002/03/14 10:00 [pubmed]
PHST- 2002/03/28 10:01 [medline]
PHST- 2002/03/14 10:00 [entrez]
AID - S0165460801005593 [pii]
AID - 10.1016/s0165-4608(01)00559-3 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2002 Feb;133(1):66-71. doi: 
      10.1016/s0165-4608(01)00559-3.